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Staphylococcus epidermidis, the common inhabitant of human skin and mucosal
surfaces has emerged as an important pathogen in patients carrying surgical implants
and medical devices. Entering the body via surgical sites and colonizing the medical
devices through formation of multi-layered biofilms leads to refractory and persistent
device-related infections (DRIs). Staphylococci organized in biofilms are more tolerant
to antibiotics and immune responses, and thus are difficult-to-treat. The consequent
morbidity and mortality, and economic losses in health care systems has strongly
necessitated the need for development of new anti-bacterial and anti-biofilm-based
therapeutics. In this study, we describe the biological activity of a marine sponge-derived
Streptomyces sp. SBT348 extract in restraining staphylococcal growth and biofilm
formation on polystyrene, glass, medically relevant titan metal, and silicone surfaces.
A bioassay-guided fractionation was performed to isolate the active compound (SKC3)
from the crude SBT348 extract. Our results demonstrated that SKC3 effectively
inhibits the growth (MIC: 31.25 µg/ml) and biofilm formation (sub-MIC range: 1.95–
<31.25 µg/ml) of S. epidermidis RP62A in vitro. Chemical characterization of SKC3 by
heat and enzyme treatments, and mass spectrometry (HRMS) revealed its heat-stable
and non-proteinaceous nature, and high molecular weight (1258.3 Da). Cytotoxicity
profiling of SKC3 in vitro on mouse fibroblast (NIH/3T3) and macrophage (J774.1) cell
lines, and in vivo on the greater wax moth larvae Galleria mellonella revealed its non-
toxic nature at the effective dose. Transcriptome analysis of SKC3 treated S. epidermidis
RP62A has further unmasked its negative effect on central metabolism such as carbon
flux as well as, amino acid, lipid, and energy metabolism. Taken together, these findings
suggest a potential of SKC3 as a putative drug to prevent staphylococcal DRIs.
Keywords: marine sponges, Streptomyces, Staphylococci, device-related infections, bioassay-guided
fractionation, transcriptome
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INTRODUCTION
Surgical implants and medical devices have greatly assisted
in improving the survival and recovery of patients from
physical ailments (Vinh and Embil, 2005). However, they also
are ideal niches for colonization and biofilm formation by
microorganisms from patient’s own skin, healthcare workers’
skin, or hospitalized settings (Percival et al., 2015). Biofilms
are networks of microorganisms that are entrapped in a self-
produced gluey matrix made up of polysaccharides, proteins,
lipids, and eDNA (Otto, 2009; Flemming and Wingender, 2010).
Microbes in biofilms exhibit 10–1000-fold increased resistance
to antibiotics and host immune systems; and a number of
mechanisms are supposed to contribute to this phenomenon
such as the presence of biofilm matrix itself, slow growth rate
and persister cell formation, eﬄux pumps, plasmid exchange,
target mutations, and antibiotic-modifying enzymes etc. (Stewart
and Costerton, 2001; Hall-Stoodley et al., 2004; Percival et al.,
2011; Rajput et al., 2018). Current treatment of biofilm based
device-related infections (DRIs) involves complete removal of
the infected implant or device by a surgical procedure followed
by prolonged antibiotic treatments (Otto, 2012). Biofilm based
infections thus, lead to increased patient morbidity and mortality,
and increased health care costs (Shida et al., 2013; Kleinschmidt
et al., 2015; Leary et al., 2017).
The majority of the DRIs reported till date are a consequence
of biofilm formation by coagulase negative (e.g., Staphylococcus
epidermidis) and positive (e.g., S. aureus) staphylococci (Mack
et al., 2007; Becker et al., 2014; Windolf et al., 2014).
Predominantly, S. epidermidis an inhabitant of skin and mucosa
is the leading cause of nosocomial and DRIs (Otto, 2009;
Franca et al., 2012; Namvar et al., 2014; Sabate Bresco et al.,
2017). The development of complications like catheter-related
blood stream infections, prosthetic joint infections, early onset
neonatal sepsis etc., and the rapid emergence of drug-resistant
staphylococcal strains in hospital and community settings has
challenged the effectiveness of current therapeutic regimes
(Barros et al., 2014; WHO, 2014; Sakimura et al., 2015;
Widerstrom, 2016). Therefore, it is imperative to develop
novel antibacterial and anti-biofilm-based therapeutics for
management of the hard-to-treat staphylococcal infections
(Bjarnsholt et al., 2013).
Marine bioprospecting has gained much attention in the
recent years owing to its massive chemical and biological diversity
(Mayer et al., 2010; Gerwick and Moore, 2012; Martins et al.,
2014; Thompson et al., 2017). A variety of bioprospecting
techniques (including cultivation-dependent to independent
approaches) have been described so far towards harnessing the
bioactive potential of the marine realm (Abdelmohsen et al.,
2015; Kodzius and Gojobori, 2015; Indraningrat et al., 2016).
Particularly, marine sponges and their associated actinomycetes
are abundant reserves of novel natural products with distinct
biological activities of pharmaceutical importance (Thibane et al.,
2010; Abdelmohsen et al., 2014a, 2015, 2017). A wide spectrum
of anti-staphylococcal compounds and extracts possessing
antibacterial and/or anti-biofilm activities have been reported
from marine sponges and microbes (Rahman et al., 2010; Stowe
et al., 2011; Beau et al., 2012; Palomo et al., 2013; Gomes et al.,
2014; Balasubramanian et al., 2017).
A preliminary anti-biofilm screening (against the model
isolate S. epidermidis RP62A) with 50 different organic extracts
obtained from solid and liquid batch fermentations of 25
different marine sponge-derived actinomycetes, led to the
identification of the bioactive extract from Streptomyces sp.
SBT348. Marine sponge-derived Streptomyces sp. SBT348 is a
Gram-positive bacterium that was previously shown to possess
distinct metabolomic and rich chemistry profiles with strong
biological activities (Cheng et al., 2015, 2017). In this study,
bioassay-guided fractionation was performed to unravel the
active component(s) in the SBT348 extract. The most active
compound SKC3 was evaluated further for growth and biofilm
inhibition on various S. epidermidis, S. aureus, and Pseudomonas
aeruginosa strains. Results obtained highlighted the specific
anti-biofilm nature of SKC3 with high potency and non-
toxic nature. Chemical analysis revealed the heat-stable, non-
proteinaceous, and high-molecular weight of SKC3 (1258.3 Da).
Finally, data from transcriptome analysis revealed the regulation
of expression of several genes related to carbon, amino-acid,
proteins, lipids, nucleotides, and energy metabolism suggesting
the possible interference of SKC3 with global metabolism of
staphylococci.
MATERIALS AND METHODS
Instrumentation
Flash chromatography was done on an Interchim Puri-Flash 430
instrument (ultra performance flash purification) connected to
an Interchim flash ELSD (Montlucon, France).
Semi-preparative HPLC of the active fraction was perfomed
with Agilent 1100 series (Waldbronn, Germany) using Gemini-
NX5u-C18-110A column (250 × 10 mm, Phenomenex,
United States) and detection at 250 nm. The following gradient
was applied solvent A: water and solvent B: acetonitrile.
Separation method: solvent B 20% for 4 min, 40% for 11 min,
40 to 50% in 5 min, 50 to 90% in 1 min, and again to 20%
in 4 min; maximum pressure of 400 bar and a flow rate of
4 ml/min.
Purity of the compound was determined with analytical
HPLC system but with Gemini-NX5u-C18-110A column
(250 × 4.60 mm, Phenomenex, United States). Separation
method: solvent B 5% at 0 min, 5 to 100% for 25 min, 100% for
1 min, 100 to 50% in 2 min, and again to 5% in 2 min; maximum
pressure of 400 bar; flow rate of 1 ml/min; wavelength of 250 nm.
Fourier transform-infrared spectroscopy (FT-IR) of SKC3
were conducted using Jasco FT/IR-6100 spectrometer with an
ATR unit (Groß-Umstadt, Germany) at room temperature.
Mass spectrometry measurements were performed using
normal electrospray ionization (ESI; in positive mode) in a
micrOTOF-QIII mass spectrometer (Bruker Daltonics, Billerica,
MA, United States) coupled to an Agilent 1100 HPLC system. ESI
was operated with a capillary voltage of 4.5 KV. Nitrogen at 200◦C
and a flow rate of 7 l/min was used as the desolvation gas. Mass
spectral data was obtained over a range of 50–3500 m/z.
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Scanning electron microscopy (SEM) was done with
JEOLJSM-7500F (Japan) with field emission gun system.
Bacterial Strains and Culture Conditions
Bacterial strains used in the work are mentioned in Table 1.
Streptomyces sp. SBT348 was grown in ISP2 medium (4 g/l yeast
extract, 10 g/l malt extract, and 4 g/l glucose in artificial sea water)
at 30◦C. All other strains in the study were cultured in Tryptic
Soy Broth (TSB; Becton Dickinson) (17.0 g/l pancreatic digest
of casein, 3.0 g/l peptic digest of soybean meal, 5.0 g/l sodium
chloride, 2.5 g/l dipotassium hydrogen phosphate, and 2.5 g/l
glucose) and incubated at 37◦C.
Large Scale Fermentation and Extract
Preparation
A total of 1,000 ISP2 agar plates (prepared with artificial
sea water) were inoculated with a week-old liquid culture of
Streptomyces sp. SBT348, respectively, and were incubated at
30◦C for 10 d (batch fermentation). Agar with bacterial biomass
was cut into small pieces and transferred into 1 l of ethyl acetate.
The solutions were subjected to shaking at 175 rpm in a shaker
overnight. Subsequently, the macerations were filtered, and the
filtrates were evaporated in vacuo to obtain the dried SBT348
organic extract. Agar plates without the actinomycetes were
extracted in a similar manner and this was the medium control
for the bioactivity testing. Extracts were dissolved in DMSO
(final concentration 3.75% v/v) and used for in vitro assays.
Additionally, SEM was done for the Streptomyces sp. SBT348 10th
day culture on the ISP2 agar plate. The SEM protocol has been
described below.
Bioassay Guided-Fractionation for
Isolation for Active Component(s)
A total of 1.2 g of the dried extract obtained was subjected
to fractionation using a flash chromatography with a
cyclohexane/ethyl acetate/methanol gradient eluent, yielding
10 major fractions. After biological evaluation of each major
fraction in vitro, against the biofilm formation of S. epidermidis
RP62A, the active fraction Fr 7 was found. Fr 7 was sub-
fractionated by semi-preparative HPLC and this yielded seven
sub-fractions (including the bioactive SKC1, SKC2, SKC3,
SKC4, and SK7). The bioactive fraction was further purified on
HPLC to yield the bioactive compound SKC3. Pure compound
SKC3 was dissolved in DMSO (final concentration 3.75% on
cells) or stored dry in amber colored vials at −80◦C to ensure
stability.
Characterization of the Active
Compound SKC3
Stability of Compound to Heat and Enzyme
Treatments
SKC3 at the respective effective concentrations was subjected to
heat (100◦C for 1◦h; followed by cooling on ice) and enzymatic
(proteinase K and trypsin; final concentration of 1 mg/ml, 37◦C
for 1 h) treatments. As controls, DMSO (final concentration of
3.75%) was subjected to similar heat and enzymatic treatments.
For each of the treatments, the growth and biofilm inhibitory
effects of treated and untreated SKC3 were assessed using the
microtiter 96-well plate assay against S. epidermidis RP62A. Each
data point is composed of three independent cultures performed
in duplicates.
Biofilm Assay and MIC Determination
Biofilm assay was perfomed as previously described
(Balasubramanian et al., 2017). Bacterial strains (OD600 ∼ 0.05
in TSB) were incubated in the presence of SBT348 extract or
SKC3 at different concentrations at 37◦C (for S. epidermidis and
P. aeruginosa) or 30◦C (for S. aureus) for 24 h. Experimental
controls included bacteria treated with ISP2 medium extract or
DMSO and TSB without bacteria. MIC was determined against
the various pathogenic bacterial strains in this microbroth
dilution assay according to CLSI protocols. OD630 values were
used to determine the MICs. MIC was determined as the
concentration of the test substance where the lowest OD630
values were recorded with no visible bacterial growth. After
OD630 measurement, the planktonic bacteria were discared by
rinsing with sterile 1× PBS (sterile) and biofilm cells were heat
fixed at 65◦C for 1 h. Plates were then stained with 0.3% crystal
violet for 5 min, washed thrice with sterile double-distilled water
and air-dried briefly. Finally, OD492 measurements determined
the extent of biofilm inhibition in test wells in comparison with
control. S. epidermidis (ATCC12228) and S. carnosus TM300
were the biofilm negative strains used in the experiment.
For studying the effect on existing or pre-formed biofilms,
biofilms were established shortly before the experiment with
the above protocol. Formed biofilms were then treated with
fresh TSB (control) or the test substance at their respective
final concentrations and incubated further at 37◦C or 30◦C
for 24 h. The extent of biofilm eradication was assessed
with the crystal violet assay. NaIO4 that digests the biofilm
matrix (polysaccharides) was used as the positive control in the
experiment.
Growth Curve Studies
The antagonistic effect of SBT348 extract and SKC3 on the
growth of S. epidermidis RP62A was determined by growth
curve measurements (Nithya et al., 2010). Briefly, SBT348 extract
or SKC3 (MIC and MBIC90) were added to tubes containing
bacteria (initial OD600 of 0.1). Tubes were incubated at 37◦C
at 200 rpm. Bacterial growth was monitored for every 2 h up
to 24 h by optical density and CFU measurements (every 4 h).
TSB medium devoid of the bacteria was used as the negative
control while medium extract or DMSO treated bacteria served
as the appropriate controls in the experiment. Three independent
cultures were used in this experiment to ensure reproducibility of
results.
Anti-biofilm Effect on Different Surfaces
The anti-biofilm effect of SBT348 extract and the compound
SKC3 was studied at their respective BICs on different surfaces;
glass cover slips (diameter of 12 mm), medically relevant
titan metal plates (diameter of 1.5 cm; University clinic for
dental, oral and jaw diseases, Würzburg, Germany), and silicone
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TABLE 1 | Strains used in this study.
Strain Origin Relevant characteristics Reference and/or source
Streptomyces sp. SBT348 Marine sponge-derived actinomycetes
strain#
Filamentous, sporulating Cheng et al., 2015
Staphylococcus epidermidis RP62A Reference strain isolated from intra-vascular
catheter associated sepsis
+++ ATCC collection
Staphylococcus epidermidis O-47 Clinical isolate from septic arthritis ++ Heilmann et al., 1996
Staphylococcus epidermidis 1457 Clinical isolate from a patient with infected
central venous catheter
+++ Mack et al., 1992
Staphylococcus epidermidis ATCC 12228 Non-infection associated strain – – – ATCC collection
Staphylococcus carnosus TM300 Meat starter culture – – – Rosenstein et al., 2009
Staphylococcus aureus Newman MSSA isolate from osteomyelitis patient + Lipinski et al., 1967
Staphylococcus aureus USA300 Lac∗ CA-MRSA isolate from a wrist abscess + McDougal et al., 2003
Staphylococcus aureus RF122 Bovine mastitis isolate – Fitzgerald et al., 2001
Staphylococcus aureus Mu50 Human MRSA isolate from surgical wound
infections, vancomycin-resistant
– Kuroda et al., 2001
Staphylococcus aureus COL Human MRSA isolate – Dyke et al., 1966
Pseudomonas aeruginosa PAO1 Clinical isolate from wound +++ Dr. Vinay Pawar, Braunschweig, Germany
Pseudomonas aeruginosa PA14 Clinical isolate from burn wound +++ Dr. Vinay Pawar, Braunschweig, Germany
# Isolated from Mediterranean sponge Petrosia ficiformis that was collected offshore Pollonia, Milos, Greece (N36.76612◦; E24.51530◦), May 2013 (GeneBank accession
No. KP238417). +++ Strong biofilm former, ++ moderate biofilm former; + weak biofilm former (in comparison with S. epidermidis RP62A), – no detectable biofilms
under conditions tested, – – – biofilm negative phenotype. Biofilm formation was assessed in TSB medium employing the standard crystal violet biofilm formation assay.
tubes (length 1 cm and 0.2 cm diameter; Biotronik, Berlin,
Germany). Briefly, 1 ml of S. epidermidis RP62A (OD600 of
0.05) was transferred to 24-well plates (Greiner bio-one, GmbH,
Germany) containing the surfaces of interest with the test
substances. Control wells containing the medium extract and
DMSO were maintained in parallel. Sterile controls containing
the surfaces with TSB alone were included to ensure absence of
contamination. All the plates were incubated at 37◦C for 24 h
under static conditions. Samples were then subjected to washing
with sterile PBS (2×) and subjected to SEM studies.
For SEM, samples were fixed overnight with gluteraldehyde
(6.25%) and washed with Sörenson buffer (100 mM KH2PO4 and
100 mM Na2HPO4). After dehydration with a series of steps with
ethanol, samples were finally coated with gold by low vacuum
sputter coating, and scanned in the electron microscopy unit,
University of Würzburg.
TABLE 2 | Effect of SKC3 on strains used in the study.
Strain MIC BIC>75
Staphylococcus epidermidis RP62A 31.25 µg/ml 3.95 µg/ml
Staphylococcus epidermidis O-47 31.25 µg/ml 7.81 µg/ml
Staphylococcus epidermidis 1457 31.25 µg/ml 15.62 µg/ml
Staphylococcus aureus Newman 31.25 µg/ml 7.81 µg/ml
Staphylococcus aureus USA300 Lac∗ 15.62 µg/ml 3.95 µg/ml
Staphylococcus aureus RF122 31.25 µg/ml ND
Staphylococcus aureus COL 15.62 µg/ml ND
Staphylococcus aureus Mu50 15.62 µg/ml ND
Pseudomonas aeruginosa PAO1 – –
Pseudomonas aeruginosa PA14 – –
MIC, minimum inhibitory concentration; BIC>75, >75% biofilm inhibitory
concentration; –, inactive; ND, not determined.
Cytotoxicity Profiling
In Vitro on Cell Lines
Cytotoxicity of the purified compound SKC3 was assessed on
macrophage (J774.1) and mouse fibroblast (NIH/3T3) cell lines
using alamar blue assay (Huber and Koella, 1993). RPMI 1640
(1×) + GlutamaxTM-1 and DMEM (1×) GlutamaxTM-1 (Life
TechnologiesTM, United States), supplemented with 10% FCS
without antibiotics, were used for culturing J774.1 and NIH/3T3
cell lines, respectively. A total of 105 cells/ml were seeded on 96-
well plates containing SBT348 extract (62.5–500 µg/ml) or SKC3
(3.95–500 µg/ml) and the plates were incubated at 37◦C with 5%
CO2 for 24 h. A total of 20 µl of alamar blue (Thermofischer
Scientific, United States) was added to each well and the plates
were incubated for a further period of 24 h at 37◦C with 5%
CO2. Finally, the OD550 values of the plates were measured and
normalized to OD630 values. Extent of cytotoxicity was measure
by comparison of extract/SKC3 treated sets with the control.
MeOH (toxic to the cells) was used as the positive control in the
experiment. DMSO at a final concentration of 1% was used as the
control.
In Vivo on Galleria mellonella Larvae
Galleria mellonella larvae (at their final stage) were purchased
from Mouse Live Bait (Balk, Netherlands). In vivo toxicity of
SBT348 extract and SKC3 was assessed in G. mellonella using
the method described previously (Gibreel and Upton, 2013; Skaf
et al., 2017). Healthy larvae (clear in color without the presence
of any spots or pigmentation) were used in the experiment.
SBT348 extract and SKC3 at their respective test concentrations
were prepared in endotoxin-free PBS (Merck, Germany) (vehicle
control) and were injected in the last left pro-leg of the larvae
with sterile insulin pens (BD Micro-FineTM + Demi). A total of
10 larvae were included per group. Negative controls included
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the group that underwent no injection and injection with vehicle
control only, while, positive control included the group injected
with pure MeOH (Roth, Germany). Larval groups were incubated
at 37◦C in petri dishes (devoid of light). Larval survival rates were
recorded every 24 h up to 120 h. Larvae that were pigmented
and did not respond to touch were scored dead and vice versa.
Experiments were repeated three independent times to ensure the
reproducibility of results.
RNA Extraction, DNase Treatment, and
RNA Quality Determination
Staphylococcus epidermidis RP62A (OD600 of 1.0) was treated
with SKC3 (62.5 µg/ml) and was statically incubated in a 6-
well plate at 37◦C for 20 min and 3 h. Treatment with DMSO
(final concentration of 3.75% v/v on the cells) served as the
appropriate control in the experiment. RNAprotect bacteria
reagent (Qiagen, Germany) was added at the respective time
points for protection and stabilization of RNA. Subsequently,
RNA isolation was done according to the customized protocol
described by Franca et al. (2012). Three independent biological
replicates each from a pool of three independent wells were
performed in order to reduce the variability. Isolated RNA
samples were subjected to treatment with Turbo DNA-freeTM kit
(Invitrogen, United States) following manufacturer’s instructions
and acid phenol:chloroform:isoamylalcohol (125:24:1) (Ambion,
United States). Finally, pure RNA samples obtained, were
precipitated with ethanol and checked for DNA contamination
by PCR for icaA gene (Supplementary Figure S1).
Concentration and purity of the total RNA was evaluated
spectrophotometrically using NanoDrop 2000 PEQLAB GmbH
(Erlangen, Germany). The ratios A260/A280 (mean values of
all the samples was 1.97) and A260/A230 (mean values of all
the samples was 2.59) were used as indicators of protein and
phenol/polysachharide contamination. Total RNA quality was
also assessed with an Agilent 2100 Bioanalyzer (Agilent, CA,
United States). RNA integrity numbers of all samples were ∼8.0
or more.
Ribosomal RNA Depletion, Library
Preparation, and Sequencing
Extracted RNA was depleted of ribosomal RNA using the
Ribo-Zero rRNA Removal Kit for bacteria (Illumina) according
to the manual. Depleted RNA was fragmented for 3 min
at 94◦C using the NEBNext Magnesium RNA Fragmentation
Module. The RNA ends were repaired with two consecutive
T4 PNK incubations (±ATP) and an RppH treatment. Library
preparation was performed according to the NEBNext Multiplex
Small RNA Library Preparation Guide for Illumina. All adapters
and primers were diluted 1:4 and 15 and 16 cycles of PCR were
used, respectively. No size selection was performed at the end of
the protocol. A total of 12 libraries were pooled and sequenced on
a NextSeq 500 with a read length of 75 nt.
Analysis of Deep-Sequencing Data
The quality of raw reads (Phred scores, amount of duplicates
and adapter) were assessed using FastQC (version-0.11.31)
(Andrews, 2010). In order to assure a high sequence quality, the
Illumina reads in FASTQ format were trimmed with a cut-off
phred score of 20 by cutadapt (version-1.15) (Martin, 2011) that
also was used to remove the adapter sequences. The following
steps were performed using the subcommand “create,” “align,”
and “coverage” of the tool READemption (Forstner et al., 2014)
(version 0.4.3) with default parameters. Reads with a length
below 15 nt where removed and the remaining reads were
mapped to the reference genome sequences (NCBI accession
no. NC_002976.3 (31 January 2014)) using segemehl (Hoffmann
et al., 2009). Coverage plots in wiggle format representing the
number of aligned reads per nucleotide were generated based
on the aligned reads and visualized in the Integrated Genome
Browser (Freese et al., 2016). Each graph was normalized to the
total number of reads that could be aligned from the respective
library. To restore the original data range and prevent rounding
of small error to zero by genome browsers, each graph was
then multiplied by the minimum number of mapped reads
calculated over all libraries. The differentially expressed genes
were identified using DESeq2 version 1.16.1 (Love et al., 2014).
In all cases, only genes with maximum Benjamini–Hochberg
corrected p-value (padj) of 0.05 were classified as significantly
differentially expressed. The data were represented as MA plots
using R.
Differentially expressed genes (cutoff of p adjusted ≤0.05 and
log2FC ≥ 2 or ≤ −2) was used to perform Gene enrichment
using the R package clusterProfiler version v3.4.4 (Yu et al., 2012).
Using enrich KEGG function enrichment in KEGG pathways
was analyzed. Only the pathways with Benjamini–Hochberg FDR
threshold ≤0.05 defined as significantly enrichment terms.
The RNA-Seq data presented in this work has been deposited
at the NCBI Gene Expression Omnibus (Edgar et al., 2002)
and can be accessed through GEO series accession number1
GSE109983. Samples treated with SKC3 has been referred to as
C3 in the submitted files.
Statistical Analysis
All the experiments were performed three independent times
with technical replicates. Data are expressed as mean ± SEM.
For all the comparisons, Student’s t-test was used. For
comparing different Kaplan–Meier survival curves from in vivo
G. mellonella experiments, log-rank (Mantel-Cox) and Gehan–
Breslow–Wilcoxon test was used. p-value <0.05 was considered
as statistically significant. GraphPad Prism R© version 6.01 was
used for statistical analysis of experimental data.
RESULTS
Anti-biofilm Potential of Streptomyces
sp. SBT348
The anti-biofilm potential of Streptomyces sp. SBT348 was
identified with a preliminary anti-biofilm screening of different
actinomycetes organic extracts against the strong biofilm forming
S. epidermidis RP62A. Streptomyces sp. SBT348 was characterized
1https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109983
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by its wrinkled, rough, dry, and light-yellow mycelia on ISP2
agar medium (t = 10 d). SEM analysis revealed the filamentous
nature of Streptomyces sp. SBT348. Branched networks with the
presence of extracellular polymeric substance-like materials were
identified in the scanning electron micrograph (Figure 1A). The
ethyl acetate SBT348 extract significantly reduced the biofilm
formation (at 24 h) in S. epidermidis RP62A (p < 0.0001).
Extract at a concentration of 62.5 µg/ml reduced the biofilm
formation by ∼90% and this was designated as the BIC90
(90% biofilm inhibition concentration). Notably, there were no
significant differences in the effect beyond this concentration
(Figure 1B). SBT348 extract at BIC90 or 2×BIC90 did not further
alter the growth pattern of S. epidermidis RP62A (compared
to extract from ISP2 medium control) (Figure 1C). SBT348
extract had no antagonistic effects on pre-formed Staphylococcus
epidermidis RP62A biofilms at any of the tested concentrations
(15.62–500 µg/ml; data not shown). Cytotoxicity profiling of
the extract in vitro on NIH/3T3 and J774.1 cell lines (Table 3)
and in vivo on G. mellonella larvae demonstrated the non-toxic
nature of the extract (Figure 1D). Further, no changes in the
activity of the extract was observed after heat and enzymatic
(proteinase K and trypsin) treatments (data not shown). This
highlighted the presence of heat-stable and non-proteinaceous
active proportion(s) in the extract.
Bioassay-Guided Fractionation and
Characterization of the Active
Compound
The bioassay-guided fractionation approach followed to identify
the active component SKC3 (MIC of 31.25 µg/ml and BIC90
of 3.95 µg/ml) in the extract that is shown in Figure 2A.
SKC3 was further investigated in detail in the study. The pure
compound SKC3 (Supplementary Figure S2) was obtained as
yellow crystalline solid and was soluble in polar solvents like
water, DMSO, and MeOH. Results obtained ESI-MS analysis
revealed that SKC3 had a neutral mass of approximately
1258.3 Da (Figure 2B). This mass was also found in the
SBT348 extract (data not shown). FT-IR spectra of SKC3
revealed some significant bands at 2,936, 3,326, 1,660, and
1,072 cm−1, representing the presence of –C–H– stretches, –
OH, amide carbonyl group, and an ester group (Figure 2C).
Mass search with 1258.3 Da in databases like MarinLit R© and
Chemspider R© did not yield any relevant hits. Further, heat and
FIGURE 1 | (A) Colony morphology and scanning electron micrograph (at ×1,500 and ×15,000 magnification) of Streptomyces sp. SBT348 after 10 d batch
fermentation on ISP2 agar plate at 30◦C. Scanning electron microscopy indicates the presence of extracellular polymeric substance-like materials in Streptomyces
sp. SBT348. Scale bar: 10 and 1 µm. (B) Dose-dependent inhibition of biofilm formation of Staphylococcus epidermidis RP62A by ethyl acetate extract of
Streptomyces sp. SBT348. (C) Influence of SBT348 extract on the growth of S. epidermidis RP62A at BIC90 (62.5 µg/ml) and 2×BIC90 (125 µg/ml).
(D) Kaplan–Meier survival curve of Galleria mellonella larvae treated with 16×BIC90−0.5×BIC90 of SBT348 extract (0.625–20 µg/larvae). Pure MeOH (20 µl) that
was toxic to larvae was used as the positive control. Control in the experiments (B–D) consisted of ethyl acetate extract (at the respective highest concentration)
from sterile ISP2 medium which was used as growth medium for Streptomyces sp. SBT348. Graphs represent the mean ± SEM from three independent repetitions
of experiment done with multiple technical replicates. ns, not significant; ∗∗∗∗p < 0.0001.
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TABLE 3 | In vitro cytotoxicity of SBT348 extract and SKC3 on cell lines.
Cell line Percentage reduction in cell viability
500 µg/ml 250 µg/ml 125 µg/ml 3.9–125 µg/ml
NIH/3T3 41.07 ± 1.37∗∗∗∗ NC NC NC
J774.1 62.91 ± 0.83∗∗∗∗ 63.90 ± 1.84∗∗∗∗ 32.78 ± 7.00∗∗∗ NC
Each data point is comprised of three independent trials done in quadruplicate. Mean ± SEM are reported. Differences in the mean were compared to the control and
considered statistically significant when p (∗∗∗p < 0.001, ∗∗∗∗p < 0.0001) calculated by Student’s t-test. SBT348 extract (62.5–500 µg/ml) exhibited no significant toxicity
on both the cell lines tested. Positive control, MeOH reduced the cell viability of NIH/3T3 by 66.73 ± 0.59∗∗∗∗ and J774.1 by 72.10 ± 2.16∗∗∗∗. NC, no cytotoxicity.
FIGURE 2 | (A) Bioassay-guided fractionation scheme employed for isolation of active compound SKC3 in the SBT348 extract. Crystal violet biofilm assay (on
96-well plate against Staphylococcus epidermidis RP62A) was done in each step for identification of active anti-biofilm fraction (Fr), sub-fraction(s) (SF), and pure
compound (SKC3). (B) Electrospray ionization-mass spectrometry spectra of SKC3. ##Mass of SKC3 molecular ion [M+H]+ of 1259.3418 Da could be seen. Neutral
mass of SKC3, 1258.3346 Da (C) Fourier transform-infrared spectroscopy of SKC3 representing the presence of strong absorption troughs at 1660 (∗), 1072, 2936,
and 3326 cm−1 (∗∗) indicating the presence of amide carbonyl, O from ester group, –CH stretch, and –OH groups. #Background signal from the instrument.
enzymatic treatments did not significantly alter the biological
activity of SKC3 (Supplementary Figure S3). This was in line
with the results obtained from the stability studies of the
extract. The absence of relevant hits with the existing mass
and spectral data indicates that SKC3 is likely to be a new
compound. The structure elucidation of SKC3 is currently under
investigation.
Antagonistic Activities of SKC3 Against
Staphylococci
SKC3 displayed an MIC of 31.25 µg/ml on S. epidermidis RP62A
and the sub-MIC concentrations (1.95–<31.25 µg/ml) effectively
inhibited the biofilm formation in the crystal violet biofilm assay
(Figure 3A). BIC90 value of SKC3 was 3.95 µg/ml. Interference
of SKC3 (MIC) with the growth of S. epidermidis RP62A was
further confirmed with the growth curve analysis (Figure 3B).
Thus, presence of SKC3 at MIC, effectively inhibited bacterial
growth (approximately 100-fold reduction in CFUs/ml; data not
shown) while SKC3 at BIC90 had no significant influence. Further,
SKC3 (at the highest tested concentration: 500 µg/ml) had no
clearing effect on existing biofilms of S. epidermidis RP62A
(Figure 3C). Complete biofilm dispersal by NaIO4 (40 mM) was
used a positive control in this experiment. SKC3 was also effective
in inhibiting the growth and biofilm formation of other strains
used in the study (Table 2). Noteworthy, SKC3 was more effective
against MSSA, MRSA, and VRSA strains used in the study, but
was ineffective against the tested Gram negative P. aeruginosa
strains.
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FIGURE 3 | (A) Inhibition of growth (MIC: 31.25 µg/ml) and biofilm formation (sub-MIC range: <31.25 µg/ml) of Staphylococcus epidermidis RP62A. Controls
consisted of biofilm negative strains S. epidermidis ATCC 12228, S. carnosus TM300, DMSO treated S. epidermidis RP62A, and sterile TSB without bacteria.
(B) Effect of SKC3 on growth (OD600) at MIC (31.25 µg/ml) and BIC90 (3.95 µg/ml), respectively. DMSO treated S. epidermidis RP62A was the appropriate control in
the growth curve analysis. (C) Influence of SKC3 on pre-formed (existing) biofilms of S. epidermidis RP62A. NaIO4 that digests the polysaccharide biofilms was used
as the positive control. All the experiments were repeated at least three times in multiple technical replicates. ns, not significant; ∗∗∗∗p < 0.0001.
SEM Analysis
Investigation of the anti-biofilm efficacy of SKC3 at sub-
MICs were further evaluated with SEM of S. epidermidis
RP62A biofilms grown on glass, titan metal, and silicone
tube surfaces. From the scanning electron micrographs, clear
differences in appearance were observed in the three sterile
surfaces under study. In the control sets of the surfaces (treated
with DMSO; 3.75%), three-dimensional dense biofilm structures
were observed. Treatment with SKC3 (BIC90 and 2×BIC90)
significantly reduced the biofilm formation on these surfaces and
this further confirmed the results obtained from crystal violet
biofilm assay (Figure 4). Particularly, the three-dimensional
networks were absent, and the surfaces were clearly seen (between
sporadic microcolonies or single cells) in the SKC3-treated sets.
A closer look on the SEM images at higher magnification revealed
no alterations in the cell morphology of staphylococci. These
findings further point towards the anti-biofilm potential of the
isolated compound SKC3.
In Vitro and in Vivo Toxicity of SKC3
In vitro toxicity assessment of SKC3 was done on mouse
macrophage (J774.1) and fibroblast cell lines (NIH/3T3) using
the alamar blue assay. Results from the cytotoxicity analysis
demonstrated the non-toxic nature of SKC3 at effective
concentrations (Table 3).
Toxicity of SKC3 was additionally assessed in vivo in
the greater wax moth larvae, G. mellonella. In recent years,
G. mellonella larvae have emerged as an interesting model system
for evaluating the toxicity and efficacy of novel compounds and
for studying various microbial infections (Gibreel and Upton,
2013; Aparecida Procopio Gomes et al., 2016; Skaf et al., 2017).
The ease of handling, low maintenance costs, absence of ethical
concerns, survival at human physiological temperatures are some
of the advantages of using G. mellonella larvae for pre-screening
of toxicity (Tsai et al., 2016). Survival rates of larvae treated
with SKC3 (BIC90–200×BIC90) are shown in Figure 5. None of
the tested concentrations lead to death of the larvae, whereas,
the positive control MeOH lead to 90% reduction in the larval
survival rates. Thus, SKC3 was completely non-toxic to the larvae
at the tested concentration.
Transcriptome Analyses of SKC3-Treated
S. epidermidis RP62A
Total RNA sequencing was done for S. epidermidis RP62A
treated with SKC3 (62.5 µg/ml) after 20 min and 3 h points.
Global transcriptome analysis with the obtained RNA sequencing
results revealed the existence of several differentially expressed
genes upon SKC3 treatment. The differentially expressed genes
were identified by setting the threshold of log2foldchange
≥ 2 or ≤ −2 with an adjusted p-value of <0.05 for statistical
significance. From the MA plots (Figures 6A,B), it is evident
that higher number of genes were differentially expressed (upon
SKC3 treatment) after 3 h than 20 min. This was additionally
confirmed in the PCA plot and a well-distributed grouping of
the different biological replicates were observed (Supplementary
Figure S4). According to the set threshold, a total of 31 genes
representing 1.1% of the transcriptome were significantly altered
in response to SKC3 after 20 min and a total of 509 genes
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FIGURE 4 | Scanning electron micrographs of Staphylococcus epidermidis RP62A (24 h) biofilms on glass cover slips, titan metal plate and silicone tubes at ×1,500
magnification (scale bar: 10 µm). Treatment with SKC3 at BIC90 and 2×BIC90 significantly reduced the staphylococcal biofilm formation on these surfaces. No
apparent changes in the morphology of RP62A (zoom in image) was observed at higher magnification (×10,000; scale bar: 1 µm).
representing 19.5% of the transcriptome were significantly
altered in response to SKC3 after 3 h. Among these genes,
29 genes were upregulated, and 2 genes were downregulated
after 20 min (Supplementary Table S1), whereas, 265 genes
were upregulated, and 244 genes were downregulated after 3 h
(Supplementary Table S2). After data filtering and searches in
PubMed and UniProtKB, the differentially expressed genes at
the two-time points were manually sorted in several categories
based on their biological functions of the products they encode.
Majority of the differentially regulated genes in the entire data
set encoded for hypothetical proteins. Transcriptome analysis
revealed that after 20 min, several of the differentially expressed
genes were attributed to signal transduction mechanism,
transporters, transcription, and antibiotic response-related
functions (Figure 6C). This suggests that S. epidermidis
RP62A responds to SKC3 by signal transduction mechanisms
and by expressing several transcription, transporters, and
antibiotic-stress related genes. Transcriptome analysis further
revealed that after 3 h, several of the metabolic processes
(pertaining to carbon, amino acid, protein, lipid, nucleotide,
and energy metabolism) and transport processes were strongly
affected (Figure 6D). Functional enrichment analysis also
yielded similar antagonistic effects of SKC3 on metabolism
(Supplementary Figure S5). A list of all differentially regulated
metabolism-related genes and virulence genes upon SKC3
treatment after 3 h are further detailed in Table 4. Overall,
the results from transcriptome analysis suggest that SKC3
possibly works by interference with the overall metabolism of
staphylococci.
DISCUSSION
The increased use of implanted medical devices, the subsequent
risk of biofilm formation on these devices and the emergence
of drug-resistant strains has altogether imposed a heavy burden
on patient and health care systems (Becker et al., 2014; WHO,
2014; Casillo et al., 2017). About, 5,027 anti-biofilm agents
against Gram-positive and negative bacteria, and fungi have
been reported between 1988 and 2017 (Rajput et al., 2018).
However, up to our knowledge none of them have been
successfully translated to the market for clinical and medical
applications. Our research aimed at harnessing the potential
of marine sponge-derived actinomycetes for discovery of novel
antibacterial and anti-biofilm compounds (Abdelmohsen et al.,
2014a,b; Dashti et al., 2014). Actinomycetes from marine sponges
represent an untapped reservoir of a wide range of unforeseen
biological compounds (Xi et al., 2012; Abdelmohsen et al.,
2015; Sun et al., 2015). Previous results have demonstrated the
anti-biofilm efficacy of an organic extract from Streptomyces
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FIGURE 5 | In vivo toxicity evaluation of SKC3 on Galleria mellonella larvae. No death was observed in the larval groups treated with vehicle control (1× PBS;
endotoxin-free) and SKC3 (BIC90 −200×BIC90). MeOH treatment lead to 90% death of the larvae.
sp. SBT343 isolated from marine sponge Petrosia ficiformis
(Balasubramanian et al., 2017). In this study, we describe the anti-
staphylococcal activity of another strain Streptomyces sp. SBT348
isolated from the same sponge. We applied a bioassay-guided
fractionation strategy to identify, isolate, and purify the active
compound responsible for this activity.
Streptomyces sp. SBT348 is a filamentous Gram-positive
bacterium that was previously shown to possess distinct
metabolomic and rich chemistry profiles with strong biological
activities (Cheng et al., 2015, 2017). SEM of the 10 d old
Streptomyces sp. SBT348 culture used for extraction and isolation
of the bioactive SKC3 indicated the presence of biofilm-like
networks (Figure 1A). This extends the possibility of SKC3 to be a
compound produced in the biofilm networks that is antagonistic
to other bacteria. However, more experiments are needed to
confirm the same.
Leary et al. (2017) proposed a combination of autoclave
and chlorhexidine treatment for complete removal of biofilms
from orthopedic materials. Alternative, coating-based strategies
have been proposed to prevent this phenomenon (Windolf
et al., 2014). The isolated compound SKC3 effectively inhibited
the growth and biofilm formation of different staphylococcal
strains (Figure 3 and Table 2). Kinetics of staphylococcal biofilm
formation in the presence of SKC3 revealed its action during early
steps of biofilm formation between 3 and 4 h (Supplementary
Figure S6). Further, the inefficacy of SKC3 against dispersing
pre-formed biofilms highlights its usage in prevention of
staphylococcal infections. This is advantageous, since, targeting
the disassembly could lead to increased inflammatory response
and severity of a disease (Franca et al., 2016). SKC3 was
also shown to inhibit the staphylococcal biofilm formation on
different medically relevant surfaces (glass, titan metal, and
silicone tubes). The non-toxic nature of SKC3 in vitro (cell lines)
and in vivo (G. mellonella larvae) explains its applicability as
antimicrobial and anti-biofilm agents on medical devices. As a
step forward, the potential of SKC3 to protect G. mellonella from
S. aureus USA300 Lac∗ was also assessed in an independent
experiment. Results obtained indicated that SKC3 could not
protect the larvae from staphylococcal infection (data not
shown). The exact reason behind this failure remains unclear.
However, further investigations are needed to evaluate the
toxicity and in vivo antimicrobial efficacy of SKC3 on higher
in vivo model systems to support its usage. The huge mass
(1258.3 Da), stability towards heat and enzymatic treatments, and
the absence of relevant hits in several databases point towards
a complex structure of SKC3. Thus, SKC3 is expected to be a
new compound and further NMR spectrometric investigations to
elucidate its complete structure are currently in progress.
Transcriptomics have been increasingly used for
understanding the responses of staphylococci to antimicrobial
agents and for obtaining insights into the antimicrobial mode of
action (Sianglum et al., 2012; Chung et al., 2013; Qin et al., 2014;
Wang et al., 2018). In our study, the global gene expression
pattern of SKC3 treated S. epidermidis RP62A was studied by
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FIGURE 6 | MA plots representing the significant gene expression changes (red dots; padj value <0.05) in SKC3 (62.5 µg/ml) treated-S. epidermidis RP62A after (A)
20 min and (B) 3 h time points in comparison with control (DMSO treated-S. epidermidis RP62A). Black dots represent the insignificant gene expression changes
(padj value >0.05). Histogram of differentially expressed genes in the presence of SKC3 (62.5 µg/ml) after 20 min (C) and 3 h (D). Results are summarized based on
biological process. X-axis indicates the number of differentially expressed genes in a category. Positive and negative axes represent the numbers of up- and
down-regulated genes, respectively. Absolute value of log2foldchange ≥2 or ≤ −2 and padj value <0.05 was used as the threshold to screen the differentially
expressed genes. UniProtKB was used to search for the biological function of differentially expressed genes.
RNA sequencing and transcriptome analysis (after 20 min and
3 h post treatment). Functional classification of all the genes
regulated by SKC3 could be seen in Figures 6C,D.
Transcriptome data from early time point (20 min) indicated
that genes encoding a two-component system (sensor histidine
kinase and response regulator), several proteins involved in
transport of macromolecules, such as ATP-binding cassette
(ABC) transporters and quaternary ammonium compound eﬄux
pumps (SugE) were significantly upregulated. ABC transporters
are often involved in multi-drug resistance by serving as eﬄux
pumps for transport of anti-infectives (Lage, 2003). SugE, a drug
eﬄux pump belonging to the small multi-drug resistance family
(SMR) was shown to be involved in resistance to a narrow range
of quaternary ammonium compounds in Escherichia coli (Chung
and Saier, 2002). However, these ABC transporters and sugE
regulated by SKC3 have not been documented to be involved in
resistance to antimicrobial compounds in S. epidermidis till date.
Further studies are needed to understand the exact roles of these
transporters and eﬄux pump in this organism. Thus, it could
be presumed that after 20 min S. epidermidis RP62A recognizes
SKC3 by a yet unknown two-component system and reacts by
expressing a variety of transporters.
Transcriptome data from the late time point (3 h) indicated
that genes encoding for hypothetical proteins were the most
differentially regulated (representing 30.64% of the total
differentially expressed genes after 3 h). Major fraction of
the known differentially expressed genes after 3 h included
the genes encoding proteins involved in global metabolism
(representing 23.37% of the total differentially expressed
genes), and transporters and membrane proteins (representing
14.73% of the total differentially expressed genes). In addition,
bacterial stress and defense related proteins were strongly
downregulated indicating the sensitivity of bacterial cells at this
time point. Like the 20 min transcriptome data, several ABC
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TABLE 4 | List of metabolism-related genes affected in response to SKC3 after 3 h.
Metabolic process and genes Function Log2fold change padj value
Carbon metabolism
glmU UDP-N-acetylglucosamine pyrophosphorylase −2.1757 3.88E-44
SERP0257 Alcohol dehydrogenase zinc-containing −2.9328 7.33E-24
fruK 1-phosphofructokinase −2.0069 7.77E-11
hprK HPr kinase/phosphatase −2.3083 3.43E-37
Pgk Phosphoglycerate kinase −2.0399 3.02E-17
tpiA Triosephosphate isomerase −2.2812 2.56E-15
Pgi Glucose-6-phosphate isomerase −3.4822 1.38E-49
pdhA Pyruvate dehydrogenase complex E1 component alpha subunit −3.1290 1.06E-26
pdhB Pyruvate dehydrogenase complex E1 component beta subunit −3.3469 7.02E-40
pdhC Pyruvate dehydrogenase complex E2 component dihydrolipoamide acetyltransferase −3.5036 1.37E-27
pdhD Pyruvate dehydrogenase complex E3 component lipoamide dehydrogenase −2.4225 1.55E-16
Pyc Pyruvate −2.7047 3.23E-51
trxA Thioredoxin −2.3877 4.66E-11
Tkt Transketolase −2.3499 1.62E-104
SERP0974 Acylphosphatase −3.7088 5.81E-45
malA Alpha-glucosidase −2.4798 3.93E-27
Gnd 6-phosphogluconate dehydrogenase decarboxylating −2.3314 5.38E-91
pfkA 6-phosphofructokinase −2.5866 9.06E-34
SERP1290 PTS system IIBC components 2.6442 1.92E-32
Tal Transaldolase −2.1920 4.46E-19
sceD SceD protein 4.8221 7.26E-69
lacR Lactose phosphotransferase system repressor 2.0861 7.09E-16
sdhA L-serine dehydratase iron-sulfur-dependent alpha subunit −2.1059 3.48E-44
SERP2112 Alcohol dehydrogenase zinc-containing −2.1470 2.46E-14
SERP2114 PTS system IIABC components −3.3405 5.78E-34
budA Alpha-acetolactate decarboxylase −2.4764 2.38E-37
budB Acetolactate synthase catabolic −3.4875 2.65E-55
ldh L-lactate dehydrogenase −3.3363 1.49E-48
SERP2345 Dihydroxyacetone kinase family protein −2.0835 3.63E-14
gldA Glycerol dehydrogenase −2.4748 1.96E-33
SERP2354 Tributyrin esterase EstA putative 2.9073 1.37E-14
pflB Formate acetyltransferase −3.6275 2.36E-49
Amino acid and protein metabolism
SERP0033 Cyclase putative 2.1197 1.70E-08
cysK Cysteine synthase −2.5176 1.47E-38
cysE Serine acetyltransferase −3.4603 1.64E-52
cysS Cysteinyl-tRNA synthetase −2.7266 4.95E-54
ilvE Branched-chain amino acid aminotransferase −2.5610 6.43E-11
SERP0349 Deoxyribodipyrimidine photolyase putative 2.1987 2.22E-18
prfB Peptide chain release factor 2 −2.5844 5.22E-23
lgt Prolipoprotein diacylglyceryl transferase −2.1091 7.12E-33
gcvH Glycine cleavage system H protein −2.4191 2.29E-23
def Peptide deformylase −2.1348 2.13E-24
def-2 Polypeptide deformylase 2.1031 4.64E-59
fmt Methionyl-tRNA formyltransferase 2.1719 7.90E-22
glnR Glutamine synthetase repressor −2.7030 7.01E-27
trpD Anthranilate phosphoribosyltransferase 4.0312 1.23E-14
trpC Indole-3-glycerol phosphate synthase 2.2689 1.50E-08
trpB Tryptophan synthase beta subunit 2.0434 6.37E-06
argB Acetylglutamate kinase 2.3225 6.68E-10
glyS Glycyl-tRNA synthetase −2.9083 1.29E-22
SERP1176 Peptidase U32 family 2.3811 1.83E-24
(Continued)
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TABLE 4 | Continued
Metabolic process and genes Function Log2fold change padj value
SERP1177 Peptidase U32 family 2.6006 3.16E-30
infC Translation initiation factor IF-3 2.3684 4.36E-17
ald Alanine dehydrogenase −2.7547 2.67E-09
SERP1292 Serine protease HtrA putative −2.7124 1.23E-30
SERP1310 Dipeptidase family protein −3.0286 8.51E-63
SERP1376 Protein export protein PrsA putative −2.6829 7.19E-41
SERP1549 Death-on-curing family protein 2.3238 1.91E-56
leuB 3-isopropylmalate dehydrogenase 2.6290 7.14E-09
glyA Serine hydroxymethyltransferase −2.3637 4.36E-33
secY Preprotein translocase SecY subunit 2.5474 1.38E-20
SERP2034 Amino acid permease family protein 3.3899 3.46E-17
SERP2043 Peptidase M42 family −3.4218 1.54E-47
cysJ Sulfite reductase (NADPH) flavoprotein alpha-component −2.1931 2.60E-23
cysH Phosophoadenylyl-sulfate reductase −2.5134 3.48E-28
arcA Arginine deiminase −2.3875 1.56E-39
sepA Extracellular elastase precursor 2.3264 4.49E-17
SERP2272 Peptide methionine sulfoxide reductase putative 2.6559 5.30E-18
SERP2276 SecA family protein 2.2325 1.96E-31
hisH Amidotransferase HisH 2.5488 6.82E-14
hisB Imidazoleglycerol-phosphate dehydratase 3.4466 1.62E-17
hisD Histidinol dehydrogenase 2.6795 3.23E-18
hisG ATP phosphoribosyltransferase 2.8203 5.58E-10
SERP2338 Peptide synthetase 2.4122 9.72E-67
SERP2364 Peptidase M20/M25/M40 family 2.6489 1.23E-16
SERP2375 Diaminopimelate epimerase family protein 2.6285 3.49E-18
serS Seryl-tRNA synthetase −2.7533 3.76E-36
Lipid metabolism
SERP0309 Lipase/esterase putative 2.2785 1.41E-11
fabH 3-oxoacyl-(acyl-carrier-protein) synthase III −2.1260 4.25E-10
plsX Fatty acid/phospholipid synthesis protein PlsX −2.1079 1.80E-60
acpP Acyl carrier protein −2.8822 7.31E-15
SERP1001 DegV family protein −2.0926 2.95E-41
SERP2337 4-phosphopantetheinyl transferase family protein 2.9365 5.06E-42
SERP2523 Glycerophosphoryl diester phosphodiesterase UgpQ putative −2.4642 8.93E-19
Nucleotide and energy metabolism
prsA Ribose-phosphate pyrophosphokinase −2.2578 1.40E-57
SERP0371 ExsD protein 6.0454 4.40E-29
SERP0372 6-pyruvoyl tetrahydrobiopterin synthase putative 5.8808 9.47E-31
SERP0373 exsB protein 5.7653 9.79E-77
folD Methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase −2.5692 3.02E-88
purE Phosphoribosylaminoimidazole carboxylase catalytic subunit −4.1495 5.44E-70
purK Phosphoribosylaminoimidazole carboxylase ATPase subunit −3.9826 4.21E-85
purC Phosphoribosylaminoimidazole-succinocarboxamide synthase −4.4226 2.61E-60
purS Phosphoribosylformylglycinamidine synthase PurS protein −4.5392 7.95E-95
purQ Phosphoribosylformylglycinamidine synthase I −4.5973 2.90E-78
purL Phosphoribosylformylglycinamidine synthase II −4.2042 6.09E-107
purF Amidophosphoribosyltransferase −4.2181 3.25E-136
purM Phosphoribosylformylglycinamidine cyclo-ligase −4.3477 2.30E-69
purN Phosphoribosylglycinamide formyltransferase −3.8846 2.36E-80
purH Phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase −3.7319 6.33E-113
purD Phosphoribosylamine – glycine ligase −2.6846 2.00E-23
purB Adenylosuccinate lyase −2.9759 1.15E-62
cdd Cytidine deaminase −2.0209 1.32E-49
(Continued)
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TABLE 4 | Continued
Metabolic process and genes Function Log2fold change padj value
thiI Thiamine biosynthesis protein ThiI 2.6751 1.97E-48
Fhs Formate – tetrahydrofolate ligase −3.4566 2.24E-39
upp Uracil phosphoribosyltransferase −2.2580 1.20E-35
adk Adenylate kinase 2.5524 1.03E-10
SERP1865 Inosine-uridine preferring nucleoside hydrolase family protein −2.0061 2.04E-09
rbsK Ribokinase −2.2333 3.77E-29
Other Metabolic processes
SERP0250 Acetyltransferase GNAT family −2.4617 3.97E-40
SERP0461 Glyoxalase family protein 2.8462 1.43E-08
SERP0556 Fumarylacetoacetate hydrolase family protein −2.1019 4.39E-07
SERP0561 Hydrolase haloacid dehalogenase-like family −2.2982 1.85E-41
SERP1178 O-methyltransferase family protein 2.3694 4.74E-47
SERP1280 Aminotransferase class V 2.7479 3.78E-43
SERP1918 Amidohydrolase family protein 2.1722 5.93E-10
SERP1996 Acetyltransferase GNAT family 2.0172 4.71E-05
SERP2054 Glycosyl transferase group 1 family protein 2.5257 1.06E-23
SERP2299 N-acetyltransferase family protein 2.6212 2.47E-16
SERP2547 YjeF-related protein 3.2688 4.13E-16
Only genes with a log2fold change ≥ 2 or ≤ −2 and a padj value <0.05 were included.
transporters, ion transporters, drug transporters, and eﬄux
pump were influenced in the presence of SKC3 after 3 h. These
are speculated to be the typical responses of S. epidermidis to
toxic agents (Putman et al., 2000; Cecil et al., 2011). However,
the specific effects of SKC3 on metabolism are much stronger.
Interference with metabolism involved differential regulation
of genes involved in carbon metabolism (down regulation of
genes related to processes of glycolysis, gluconeogenesis, pentose
phosphate pathway, glycerol, fructose, and lactose metabolism),
lipid metabolism (repression of genes related to fatty acid
biosynthesis and phospholipid metabolism), nucleotide and
energy metabolism (repression of several genes related to purine
biosynthetic process from de novo and salvage pathways), and
amino acid, and protein metabolism (repression in biosynthesis
of cysteine, isoleucine, leucine, valine, glycine, glutamine, and
lipoproteins; repression of alanine and arginine catabolism;
up regulation in biosynthesis of tryptophan, arginine, and
histidine).
Particularly, the purEKCSQLFMNHD operon, purA, purB, and
purR genes responsible for de novo purine biosynthesis were
the heavily downregulated genes in SKC3-treated S. epidermidis
RP62A (Supplementary Figure S7). Purine biosynthesis is vital
for various cellular processes and bacterial growth. The purine
biosynthetic process involves conversion of 5′-phosporibosyl-
α-pyrophosphate (PRPP) to inositol monophosphate (IMP). IMP
is then converted to adenosine monophosphate (AMP) and
guanosine monophosphate (GMP) in independent steps. Purine
biosynthesis is costly to the cell involving the consumption of
ATPs in multiple steps. The repression of purine biosynthesis
by SKC3 could lead to reduced energy production, amino
acid biosynthesis, and DNA synthesis in staphylococci. Thus,
the staphylococcal cells could get metabolically stressed in the
presence of SKC3. Further, defects in purine biosynthesis are
known to negatively affect the biofilm formation. Mutations in
purine biosynthetic genes of Photorhabdus temperata (purL),
Streptococcus sanguinis (purB and purL), Burkholderia sp. (purL,
purM, and purT), and Pseudomonas fluorescens Pf0-1 (purD,
purH, purL, purC, purM, purF, purK, and purE) led to a defect
in the biofilm formation of these bacteria (Ge et al., 2008;
Ruisheng and Grewal, 2011; Kim et al., 2014a,b; Yoshioka and
Newell, 2016). purR in staphylococci was also previously reported
to indirectly regulate biofilm formation through an indirect
mechanism (Mack et al., 2007). In a recent study, mutants
of purEKCSQLFMNHD operon, purA, purB, and purR genes
obtained by genome-wide screening of transposon library in
S. aureus USA300 were shown to possess altered microcolony
(biofilm) formation and growth on an agar plate model
(Wermser and Lopez, 2018). Interestingly, there was no direct
remarkable influence of SKC3 on the transcription of ica locus
(3 h) encoding the polysaccharide intercellular adhesin (PIA)
responsible for biofilm formation in S. epidermidis. Instead,
virulence factors like the phenol soluble modulins α and β
(proinflammatory cytolysins) involved in biofilm structuring and
detachment processes (Otto, 2009; Fey and Olson, 2010) and
hemolysin (putative) were down-regulated. From these findings,
it could be perceived that SKC3 could possibly repress the
staphylococcal biofilm formation via downregulation of purine
biosynthetic genes. However, further research on the regulatory
linkage between purine metabolism and biofilm formation is
needed.
Overall, it is evident from the data that SKC3 has multiple
metabolic targets including several unexploited pathways. The
antagonistic effect of SKC3 on staphylococcal metabolism is
in line with the findings from previously reported antibiotic
compounds. Various natural products and anti-staphylococcal
compounds like betulinaldehyde, benzimidazole
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derivatives, bisquaternary bisnapthalimide, isoquinolines, lupeol,
rhodomyrtone, and stigmasterol were previously shown to
interfere with staphylococcal metabolism (involving interference
with processes like carbon metabolism, DNA metabolism and
replication, fatty acid biosynthesis, purine metabolism, synthesis
of ribosomal proteins, transport of compounds, etc.) (Cecil et al.,
2011, 2015; Menzel et al., 2011; Sianglum et al., 2012; Chung et al.,
2013; Adnan et al., 2017; Kong et al., 2018).
In conclusion, the anti-biofilm compound SKC3 was isolated
from the chemically diverse strain Streptomyces sp. SBT348
with the aid of bioassay guided-fractionation. SKC3 exhibited
antagonistic effects against growth and biofilm formation (at
concentrations less than MICs) of several staphylococcal strains
tested without exhibiting apparent in vitro and in vivo toxicity.
Transcriptome analysis revealed the interference of SKC3 with
several metabolic processes (carbon, protein, lipid, nucleotide,
and energy metabolism) of staphylococci. However, further
experimental data is needed to elucidate the exact anti-
staphylococcal mode of action of SKC3.
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